Immuno-oncology: Is it a new hope for cancer patients?
Journal Title: Cancer Studies & Molecular Medicine – Open Journal - Year 2015, Vol 2, Issue 1
Abstract
Cancer is the one of the leading causes of death, whose incidences is increasing day by day due to lack of understanding about its complete mechanism. Therefore, to understand complete mechanism of cancer, researchers started to move their focus from the cancer cell to the host and the environment in which the cancer grows, a very important component of which is the immune system.1,2 The immune system comprises of innate and adaptive system which provides protection to the body against pathogens. The immune cell receptors recognize the foreign and activate the complex immune response signaling pathways which results in the elimination of pathogens.3,4 The first problem with cancer cells is that they arise from our own cells, so some times unable to recognize as non self. Further, if they recognized, alters the immune response signaling pathways at various steps which results in failure of immune response. The cancer cells can avoid recognition and elimination by altering the immune response signaling pathways at various steps such as disrupting antigen recognition and presentation mechanisms, down regulates the MHC class I molecules or inhibiting the antigen processing mechanisms. Additionally, cancer cells may disrupt the pathways which are involved in controlling T-cell inhibition and activation, or by recruiting regulatory T cells (Treg) and Myeloid-derived suppressor cells (MDSC) which are immunosuppressive. Further, cancer cells may release of some of immunosuppressive immune factors such as adenosine and prostaglandin E2, and the enzyme Indoleamine 2,3-dioxygenase (IDO) which leads to progression of cancer.
Authors and Affiliations
Anoop Kumar
Keywords
Related Articles
- EP ID EP552140
- DOI 10.17140/CSMMOJ-2-108
- Views 97
- Downloads 0
Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is...
Rounding Down Chemotherapeutic Agents to the Nearest Vial Size as a Cost Containment Measure
Background: High cancer treatment costs significantly affect health care expenditures. Drug waste reduction of costly drugs can reduce the treatment cost. Methods: A retrospective study conducted at King Abdulaziz Medica...
Regulation in Cell Cycle via p53 and PTEN Tumor Suppressors
One of the target effectors of p53 transcription factor is the Phosphatase and Tensin homologue deleted on chromosome 10 (PTEN) which has protein phosphatase activity and lipid phosphatase activity that antagonizes PI3K...
Flavones and Flavonols may have Clinical Potential as CK2 Inhibitors in Cancer Therapy
The serine-threonine kinase CK2, which targets over 300 cellular proteins, is over expressed in all cancers, presumably reflecting its ability to promote proliferation, spread, and survival through a wide range of comple...
Dosimetric Characterization of an Abscopal Response in a Patient With Oligometastatic Melanoma Undergoing Concurrent Treatment With Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)
Recently, preclinical and clinical evidence has shown that a synergy may exist between radiation and immune check-point therapies such as pembrolizumab. Radiation has been shown to activate the immune system, and in comb...